Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
| Treament | Trials | |||||
|---|---|---|---|---|---|---|
| clinical deterioration | clinical improvement | deaths | viral clearance | |||
| Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) | - | - | 0.20 [0.02; 1.72], 1 RCT, I2=0% inconclusive result | - | ||
| Janssen AD26 vaccine (JNJ-78436735) | - | - | 0.19 [0.04; 0.81], 1 RCT, I2=0% unassessable degree of certainty | - | ||
| CanSino (Convidecia) | - | - | - | - | ||
| Sputnik V (Gam-COVID-Vac) | - | - | - | - | ||
| Covishield (Oxford/AZ formulation) | - | - | - | - | ||
| Ad26.RSV.preF (respiratory syncytial virus) | 0 | - | - | - | - | |
| Ad26.ZEBOV () | 0 | - | - | - | - | |
| Ad26.ZIKV.001 (Ad26-Vectored Anti-Zika Virus Vaccine) | 0 | - | - | - | - | |
| SPUTNIK-LIGHT | 0 | - | - | - | - | |
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
